1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

  • February 2014
  • -
  • GlobalData
  • -
  • 58 pages

Summary

Table of Contents

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Brexpiprazole is a D2-preferring D3/D2 receptor partial agonist in development by Otsuka. As a partial agonist, like cariprazine (a D3 partial agonist), brexpiprazole helps to stabilize dopaminergic tone in periods of hyper- or hypoactivity. Brexpiprazole has broad activity across multiple monoamine systems, including 5-HT1A partial agonism and antagonism at 5-HT2A a1 receptors, which may lessen the occurrence of EPS, although it acts on D2 receptors (Stahl, 2013). Brexpiprazole is also an antagonist at 5-HT7 receptors, which may make it useful as an antidepressant. Given its diverse activity profile, it is also being investigated in dementia, ADHD, PTSD, sleep disorders, and MDD. As its name suggests, brexpiprazole may be considered as a successor to Otsuka’s Abilify (aripiprazole), which faces patent expiration in April 2015.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Brexpiprazole for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Brexpiprazole performance
- Obtain sales forecast for Brexpiprazole from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Antipsychotic Drugs Market By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application (Schizophrenia, Bipolar disorder, Dementia, Unipolar Depression) And Segment Forecasts, 2014 - 2025

Antipsychotic Drugs Market By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application (Schizophrenia, Bipolar disorder, Dementia, Unipolar Depression) And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • February 2017
  • by Grand View Research

The global antipsychotic drugs market is expected to reach USD 14.4 billion by 2025, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products ...

Opportunity in Antipsychotics in global market - 2017

Opportunity in Antipsychotics in global market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...

Sulpiride Sales, Price Analysis, & Sales Forecast - 2017

Sulpiride Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Sulpiride Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Sulpiride worldwide and by countries in North America, Europe, Japan, BRIC, ...


Download Unlimited Documents from Trusted Public Sources

Antipsychotic Market in the Netherlands

  • April 2017
    9 pages
  • Antipsychotic  

  • Netherlands  

View report >

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Psychotic Disorder Statistics in the US

  • April 2017
  • Psychotic Disor...  

    Antipsychotic  

  • United States  

View report >

Global Therapy Market

10 days ago

Global Therapy Market

10 days ago

Anti-infective Market

24 days ago

Related Market Segments :

Antipsychotic
Psychotic Disorder

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.